Followers | 4053 |
Posts | 151055 |
Boards Moderated | 3 |
Alias Born | 08/05/2009 |
Monday, January 13, 2014 7:31:09 AM
BEAM
Recent BEAM News
- Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) • GlobeNewswire Inc. • 03/26/2024 10:30:00 AM
- Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences • GlobeNewswire Inc. • 02/28/2024 11:30:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/27/2024 12:40:17 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/27/2024 12:22:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 11:43:02 AM
- Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones • GlobeNewswire Inc. • 02/27/2024 11:30:00 AM
- Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference • GlobeNewswire Inc. • 02/05/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:05:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:05:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:05:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:05:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:05:06 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/31/2024 09:47:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 11:55:18 AM
- Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones • GlobeNewswire Inc. • 01/08/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 09:30:09 PM
- Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/02/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/14/2023 09:05:55 PM
- Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors • GlobeNewswire Inc. • 12/14/2023 11:30:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/20/2023 09:20:20 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2023 12:30:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 12:00:08 PM
- Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/08/2023 11:30:00 AM
- Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference • GlobeNewswire Inc. • 11/08/2023 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/01/2023 08:30:07 PM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM